Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

U.S. pharmaceutical imports surged in March, exceeding $50 billion, as drugmakers stockpiled inventory in anticipation of ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential tariffs on their products, which ...

The US merchandise-trade deficit with Ireland soared to a record in March on a massive inflow of pharmaceuticals and ...

Valued at $209.8 billion by market cap, Merck & Co., Inc. (MRK) is a global pharmaceutical powerhouse headquartered in Rahway ...

WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for first quarter ...

At this time, I would like to welcome everyone to the Jacobs fiscal second-quarter 2025 earnings conference call. (Operator Instructions) Thank you. And I would now like to turn the conference over to ...

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they ...

Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrierData presented at Digestive Disease Week in San ...

Merck & Co. is strutting into the spotlight as a top contender among the most profitable cheap stocks, thanks to its robust ...